Indivior Pharmaceuticals Inc (INDV) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Indivior Pharmaceuticals Inc   (NASDAQ: INDV)


Indivior Pharmaceuticals Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Indivior Pharmaceuticals Inc's ROI in the second quarter of 2026?
Indivior Pharmaceuticals Inc achieved a return on average invested assets (ROI) of 71.88 % in its second quarter of 2026, this is above INDV's average return on investment of 33.23%.
Indivior Pharmaceuticals Inc invested over the 12 months ending in its second quarter of 2026 $495 million

ROI has improved compared to 37.77% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 11 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 74 to 104.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -10.77 % 233.63 % 2701.08 % - -
Y / Y Net Income Change TTM 229.63 % - - - -
Investment (TTM) in Millions 365 404 785 427 1,053
Return On Investment (TTM) 71.88 % 37.77 % 32.25 % 23.08 % 19.46 %
INDV's Overall Ranking # 104 # 74 # 65 # 61 # 136
Seq. Investment Change TTM -25.78 % 2.46 % 17.45 % -0.09 % 177.5 %
Seq. Net Income Change TTM 41.27 % 20 % 64.06 % 18.52 % -
Net Income (TTM) in Millions 356 252 210 128 108

INDV Company Profile >> Back to INDV Roi Comparisons >> See Annual INDV Return On Investment



Return On Investment INDV's Ranking
Within: No.
Industry # 3
Sector # 12
Overall # 104

Return On Investment Statistics
High Average Low
90.36 %
33.23 %
-3.25 %
(Jun 30 2026)   (Mar 31 2025)







Financial Statements
Indivior Pharmaceuticals Inc's II. Quarter Investments $ 365 Millions INDV's Balance sheet
Indivior Pharmaceuticals Inc's II. Quarter Income $ 122 Millions Quarterly INDV's Income Statement
INDV's Income by Division See INDV's Income by Division


INDV Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023

Total Investments in Millions 291 398 429 0 0
Y / Y Investment Growth -26.88 % -7.23 % - - -
Net Income in Millions 210 2 2 0 0
Y / Y Net Income Growth 10400 % 0 % - - -
Annual Return On Investment 72.16 % 0.5 % 0.47 % - -


Annual Roi Comment
In the fiscal year 2025 ROI improved to 72.16 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
INDV's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for INDV's Competitors
Subscribers only: Roi for Indivior Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for INDV's Customers

Other Ratios
INDV's Roa INDV's Inventory Turnover Ratio INDV's Growth Rates INDV's Dividend Statistics
INDV's Profitability Ratios INDV's Asset Turnover Ratio INDV's Dividend Growth
INDV's Roe INDV's Valuation Ratios INDV's Financial Strength Ratios INDV's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Elutia Inc   191.75 %
Sanuwave Health Inc   167.92 %
Vor Biopharma Inc   162.71 %
Capforce Inc   161.42 %
Kyntra Bio Inc   157.74 %
Silexion Therapeutics Corp  127.60 %
Quince Therapeutics Inc   112.49 %
Pulmatrix Inc   108.83 %
Interpace Biosciences Inc   100.71 %
Rigel Pharmaceuticals Inc  89.00 %
Oncotelic Therapeutics Inc   87.35 %
Arbutus Biopharma Corp  85.89 %
Actinium Pharmaceuticals Inc  84.38 %
Exelixis Inc   82.05 %
Lensar Inc   75.31 %
Ironwood Pharmaceuticals inc   70.54 %
Oramed Pharmaceuticals Inc  68.90 %
Indivior Pharmaceuticals Inc   68.79 %
Rallybio Corporation  68.28 %
Fortress Biotech Inc   68.27 %
Earth Science Tech Inc   64.38 %
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %
Tg Therapeutics Inc   39.26 %

Date modified: 2026-09-12T18:35:12+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.